Endolumik

Endolumik

Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $2.5M

Overview

Endolumik is a private, pre-revenue medical device startup founded in 2018, originating from surgeon-led innovation at West Virginia University. The company has developed a novel, patent-pending surgical device that integrates NIR fluorescence guidance directly into a gastric calibration tube (bougie), addressing a critical visualization gap in sleeve gastrectomy and related procedures. By making the calibration tube clearly visible through tissue with standard NIR/ICG-capable equipment, Endolumik aims to standardize surgery, reduce adverse events like stapling errors, and improve operating room workflow. The company is currently in the commercial preparation stage, exhibiting at surgical conferences and gathering clinical validation from key opinion leaders.

ObesityGastrointestinal Disorders

Technology Platform

A fluorescence-guided surgical (FGS) platform centered on a near-infrared (NIR) lighted gastric calibration tube (bougie) with integrated suction. It is designed for universal compatibility with existing NIR/ICG-capable laparoscopic and robotic imaging systems.

Funding History

1
Total raised:$2.5M
Seed$2.5M

Opportunities

The global rise in bariatric surgery, particularly sleeve gastrectomy, provides a large and growing addressable market for a single-use, essential device.
The system's compatibility with existing robotic and laparoscopic NIR equipment lowers hospital adoption barriers and aligns with the trend toward advanced visualization in surgery.

Risk Factors

Key risks include delays or failure in obtaining FDA 510(k) clearance, slow surgeon adoption despite clearance due to procedural inertia, and potential future competition from larger medical device companies with greater commercial resources.

Competitive Landscape

Endolumik appears to be first-to-market with a dedicated NIR-illuminated gastric calibration tube. Competition likely comes from traditional, non-illuminated bougies (the current standard) and alternative visualization methods like intraoperative endoscopy or the use of ICG dye sprayed or injected near the tube. The company's integrated, device-centric approach is its key differentiator.